From treatable traits to GETomics in airway disease: moving towards clinical practice
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
With the objective of accelerating progress in research and clinical practice relating to such a treatable traits approach, the Portraits event was convened in Barcelona, Spain, in November 2022.
Here, while reporting the key concepts that emerged from the discussions during the meeting, we review the current state of the art related to treatable traits and chronic respiratory diseases management, and we describe the possible actions that clinicians can take in clinical practice to implement the treatable traits framework.
Furthermore, we explore the new concept of GETomics and the new models of research in the field of COPD.
Puedes leer el artículo completo aquí: https://pubmed.ncbi.nlm.nih.gov/38232989/
Autores: Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí.
Noticias relacionadas
RESPrimaria 1ª Edición: 8 de Mayo de 2024 en formato híbrido
Más de 900 sanitarios se reunirán de forma presencial y online, este miércoles en Barcelona, para mejorar la prevención y el tratamiento de las
patologías respiratorias.
TRIPLE THERAPY AND CLINICAL CONTROL IN B+ COPD PATIENTS: A PRAGMATIC, PROSPECTIVE, RANDOMIZED TRIAL
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
COPD in the 21st Century
COPD in the 21st Century: Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
Resumen del Primer Encuentro Anual de Pacientes de Chiesi – Chiesi PatientTalks
Primer Encuentro Anual de Pacientes de Chiesi: punto de encuentro de referencia y foro de debate y discusión para pacientes, profesionales sanitarios, así como otros agentes del sector salud, con el fin de ayudar a visibilizar sus necesidades.
V Congreso Experiencia de Paciente
El 22/02/2024 se celebrará el V Congreso del Instituto de Experiencia del Paciente (IEXP). El Dr. Alvar Agustí participará en la Mesa: Innovación en procesos y tecnología desde la experiencia de paciente.
Reunión «Chiesi PatienTalks» con la participación de Alvar Agustí como moderador
Alvar Agustí participará como coordinador científico de la Reunión “CHIESI PatienTalks” que con el patrocinio de Chiesi, se llevará a cabo el miércoles 29 de noviembre de 2023 en la Real Academia de Medicina de Barcelona.
Artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Imagen obtenida en Canva Pro.